Evaluating the Safety and Usefulness of an Investigational Study Drug for Treating Patients with Bipolar Depression
Official Title
Depressive Episodes Associated with Bipolar I or II Disorder: A Double-Blind,
Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of
ABBV-932
Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of
ABBV-932
Purpose
The purpose of this study is to see if the investigational study drug is safe and useful for treating patients with bipolar depression.
Eligible participants will be randomized to receive the drug or placebo. A placebo looks just like the investigational study drug but has no active drug in it.
The maximum duration of the study treatment period is 6 weeks. Participants receive psychiatric evaluation at each visit, and physical exam, urine test and blood draws at some of the visits. All study medication and procedures are provided at no cost, and participants may be compensated for their time and travel for each visit attended.
Could this study be right for you?
A diagnosis of bipolar disorder (type I or II) and be currently depressed.